BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.2.1//EN TZID:Asia/Jerusalem X-WR-TIMEZONE:Asia/Jerusalem BEGIN:VEVENT UID:1158@biology.technion.ac.il DTSTART;TZID=Asia/Jerusalem:20230125T130000 DTEND;TZID=Asia/Jerusalem:20230125T140000 DTSTAMP:20230115T131359Z URL:https://biology.technion.ac.il/en/seminars/phd-graduate-seminar-inbar- arman/ SUMMARY:PhD Graduate Seminar- Inbar Arman [No Categories] DESCRIPTION:Location: hybrid- in the Faculty Auditorium/ZOOM: https://tech nion.zoom.us/j/99468656897 \n Affiliation: \n Host:Prof. Reiter Yoram\n I mmunomodulation of EAE with Antibodies Targeting Autoreactive T-Cell Epito pes\n\n \;\n\nMultiple sclerosis (MS) is a demyelinating autoimmune di sease influencing more than 2.5 million people around the world. Damage ca used in this disease\, which is mediated by auto-reactive CD4+ T cells\, d isrupts nerve cell signaling\, resulting in variety of symptoms\, such as blurred vision\, muscle stiffness and numbness. Previous studies suggested that human MS disease is associated with HLA-DR2 (DRB1*1501) MHC class II allele. Presentation of myelin associated epitopes\, such as myelin oligo dendrocyte glycoprotein (MOG) on HLA-DR2 by Antigen Presenting Cells (APCs ) to autoreactive CD4+ T cells in a pro-inflammatory context\, results in autoreactive T cell activation and consequently demyelination and nerve ce lls damage. Since MHC:TCR interaction is the immune response core driving force and is also the most specific check-point in the inflammatory proces s\,   targeting myelin associated epitopes presented in the context of M HC class II molecules by APCs may decrease myelin-specific autoreactive CD 4+ T cell activation and consequently reduce the inflammatory process duri ng MS. This goal may be achieved using T cell receptor like (TCRL) antibod y- based (a) Chimeric Antigen Receptor (CAR) T cells\, targeted against my elin associated epitopes presented by APCs\, aiming for APCs destruction/s uppression or (b) TCRL-PDL1 conjugated molecule\, targeted against both PD 1+ autoreactive T cells and myelin associated epitopes presented by APCs\, delivering specific immune response attenuation against self\, mediated b y the TCRL arm\, while inducing local autoreactive T cell inhibition via t he PD-L1 arm. Accordingly\, we have isolated and characterize TCRL antibod ies with specificity toward MOG/DR2 epitope and tested their MS therapeuti c effect as MOG/DR2-CAR-T cells and MOG/DR2-PDL1 bi-specific molecules. Ou r results suggests that anti-MOG/DR2-CD8+ CAR T cells show specific elimin ation of MOG/DR2 presenting APCs in-vitro\, but exacerbate disease symptom s in-vivo\, while anti-MOG/DR2 CAR T regulatory cells induce autoreactive T cell inhibition ex-vivo and should be further examined in-vivo. Also\, a dministration of anti-MOG/DR2-PDL1 bi-specific molecules induce target-spe cific autoreactive T cell inhibition ex-vivo but shows inconclusive result s in-vivo and accordingly should be further optimized and examined as MS t herapeutic tool. LOCATION: hybrid- in the Faculty Auditorium/ZOOM: https://technion.zoom.us/ j/99468656897 END:VEVENT BEGIN:VTIMEZONE TZID:Asia/Jerusalem X-LIC-LOCATION:Asia/Jerusalem BEGIN:STANDARD DTSTART:20221030T010000 TZOFFSETFROM:+0300 TZOFFSETTO:+0200 TZNAME:IST END:STANDARD END:VTIMEZONE END:VCALENDAR